A Case report: Initial diagnostic and management of MIS-C in Community hospital
Abstract
Coronavirus disease (COVID-19) is an infectious disease that occurred in December2019 [1], caused by SARS-CoV-2 virus. It can be curable without a specific treatment [2]. At present COVID-19 isspreading all over the world and transmitted in children and adults
but the signs and symptoms of COVID-19 are less in children than adults [3-5]. Therefore,it has been found that children may have a history of COVID-19 infection, making them miss the complication of COVID-19 known as the Multisystem inflammatory syndrome
in children (MIS-C), which necessarily requires patients’ medical history, physical examination, and specific laboratory test results that are limited and different according to capacity of each hospital. This case is reported in order to serve as an early detection of MIS-C in community hospitals in which laboratory investigation and primary management can be sent according to hospital capacity before patients are referred to tertiary care hospitals.
Downloads
References
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
Coronavirus disease(COVID-19). Health Topic. World Health Organization.Availablefrom: https://www.who.int/health-topics/coronavirus.
Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children&adolescents(MIS-C): a systematic review of clinical features and presentation. PaediatrRespir Rev. 2021;38:51–7.
Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020. Epub 2020/03/01
Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points
from adults. PediatrPulmonol. 2020;55:1169-74.
COVID-19 Treatments and Medications. Centresfor Disease Control and Prevention. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html
Stephen Freedman, Shana GodfredCato, Richard Gorman, Rakesh Lodha, Lynne Mofenson, Srinivas Murthy, et al. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. World Health Organization. Available from: https://www.who.int/newsroom/commentaries/detail/multisysteminflammatory-syndrome-in-children-andadolescents-with-covid-19
Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Centres for Disease Control and Prevention. Available from: https://www.cdc.gov/mis/mis-c/hcp/index.html
Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory
Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022;74:e1-e20.
Pruthi S, Acosta AJ, Arora AS, et al. Multisystem inflammatory syndrome in children (MIS-C) and COVID-19. Mayo Clinic. 2020. Available from: https://www.mayoclinic.org/diseases-conditions/misc-in-kids-covid-19/symptoms-causes/syc-20502550
Samkoses R, Chotpitayasunondh T, Chokephaibulkit K, et al. Guideline for diagnostic and treatment of Multisystem inflammatory Syndrome in Children;M I S -and Hyperinflammation in Pediatric COVID-19 in Thailand. 2565;3:2-13.
Ahmed M, Advani S, Moreira A, et al . Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine. 2020;26:100527. Available from: 10.1016/j.eclinm.2020.100527
Ouldali N, Toubiana J, Antona D, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins
Alone With Course of Fever in Multisystem Inflammatory Syndrome inChildren.JAMA.2021;325:855–864.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
